tetano
Editor, Senior Moderator
Sci Rep
. 2020 Jun 9;10(1):9294.
doi: 10.1038/s41598-020-66440-9.
Sofosbuvir as a Potential Alternative to Treat the SARS-CoV-2 Epidemic
Rodrigo J?come[SUP] 1 [/SUP], Jos? Alberto Campillo-Balderas[SUP] 1 [/SUP], Samuel Ponce de Le?n[SUP] 2 [/SUP], Arturo Becerra[SUP] 1 [/SUP], Antonio Lazcano[SUP] 3 4 [/SUP]
Affiliations
Abstract
As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
. 2020 Jun 9;10(1):9294.
doi: 10.1038/s41598-020-66440-9.
Sofosbuvir as a Potential Alternative to Treat the SARS-CoV-2 Epidemic
Rodrigo J?come[SUP] 1 [/SUP], Jos? Alberto Campillo-Balderas[SUP] 1 [/SUP], Samuel Ponce de Le?n[SUP] 2 [/SUP], Arturo Becerra[SUP] 1 [/SUP], Antonio Lazcano[SUP] 3 4 [/SUP]
Affiliations
- PMID: 32518317
- DOI: 10.1038/s41598-020-66440-9
Abstract
As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.